Coverage
-
January 14, 2014
Allergan Inc. halted four competing drugmakers' attempts to produce generic versions of its glaucoma drug Lumigan on Monday, when a Texas federal judge ruled that their proposed products would infringe five patents for the brand-name drug.
1 other articles on this case.
View all »